In 1996, a small startup was founded in Hyderabad with a vision to create affordable healthcare solutions for the developing world. Today, as Bharat Biotech celebrates 30 years of operations, it stands as a global titan in biotechnology. Under the visionary leadership of Dr. Krishna Ella and Suchitra Ella, the company has transformed India from a vaccine-importing nation into a global pharmacy that provides essential shots to billions worldwide.

A Legacy of Firsts: Bharat Biotech’s journey is marked by groundbreaking milestones. They were the first in the world to develop a Zika virus vaccine candidate and the first to launch a clinically proven typhoid conjugate vaccine (Typbar TCV). While the world remembers them for ‘Covaxin’—India’s indigenous COVID-19 vaccine that saved millions—the company’s contribution to fighting Rotavirus and Polio has been equally monumental. Their business model has always prioritized “innovation for the masses,” ensuring that life-saving drugs are not just a luxury for the rich.

Driving Global Health Policy: Today, Bharat Biotech holds a portfolio of over 16 vaccines and exports to more than 65 countries. Their products are a staple in the World Health Organization’s (WHO) global procurement lists. As they hit the 30-year mark, the organization is looking toward the future with plans to tackle Malaria and Tuberculosis. Bharat Biotech’s story is not just about corporate success; it is a narrative of Indian grit and scientific prowess that has fundamentally altered the landscape of global public health.